Conditions: Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 136
Healthy volunteers: no

Brief summary:
This clinical study will assess efficacy and safety of indacaterol (150㎍ o.d.) in patients with Chronic Obstructive Pulmonary Disease (COPD) with destroyed lung by tuberculosis.

Detailed description:
There are few clinical studies in patients with COPD with destroyed lung by tuberculosis because tuberculosis patients are usually excluded from (phase II or III) clinical trials for drug registration although they are not prohibited from prescription of COPD drugs.

This clinical study will assess efficacy and safety of indacaterol (150㎍ o.d.) in patients with COPD with destroyed lung by tuberculosis.

Arms:
arm 1: Indacaterol 150 µg once daily arm 2: Placebo once daily

Interventions: intervention 1: Indacaterol intervention 2: Control
Intervention descriptions: intervention 1: Indacaterol 150µg once daily oral inhalation intervention 2: Placebo once daily oral inhalation

Protocol document: